Marsh & McLennan Companies, Inc. vs Relay Therapeutics Inc. Common Stock — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B), while Relay Therapeutics Inc. Common Stock trades at $17.88 (market cap $3.82B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 22.1× Relay Therapeutics Inc. Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Relay Therapeutics Inc. Common Stock for 0 Days on average.
| MRSH | RLAY | |
|---|---|---|
Market Cap | $84.31B | $3.82B |
Volume | 3,948,947 | 4,332,079 |
Sector | Financials | Health |
52-Week High | $207.02 | $20.75 |
52-Week Low | $157.32 | $6.03 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $104.99B | $2.93B |
Dividend Yield | 2.24% | — |
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $175.76, up 1.21% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust fundamentals, including a 25.72% ROE and 14.24% net income margin, alongside the recent acquisition of Accel Holdings announced on October 2, 2026. Revenue has grown steadily, reaching $27.0B in 2025, though profit margins have slightly softened.
The outlook remains positive with a consensus price target of $202.71, implying 15% upside, but risks include high valuation multiples and competitive pressures. Analysts are predominantly neutral, with 65% hold ratings, suggesting cautious optimism amid solid operational performance.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →